Ketamine as a possible cause of delirium

Journal of Pharmacy Practice and Research

Volumn 32, Issue 3, 2002, Pages 212-214

  Wein, Simon ^a   Spruyt, Odette ^a   Chapman, Rebecca ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYCLIZINE; DEXAMETHASONE; DIAZEPAM; FENTANYL; KETAMINE; OLANZAPINE; PHENYTOIN; SUFENTANIL;

ADULT; ARTICLE; CANCER PAIN; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; DELIRIUM; DEPERSONALIZATION; DEPRESSION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MEMORY DISORDER; NAUSEA; PALLIATIVE THERAPY; SEIZURE; SENSORY DYSFUNCTION; VIVID DREAM; VOMITING;

EID: 0036760920     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2002323212     Document Type: Article

References (14)

1. Wein S. Cancer. In: Psychiatric Treatment of the Medically Ill. Neel09400w York: Marcel Decker, Inc.: 1999. p. 229-54.
2. Nicholas LM, Lindsey BA. Delirium presenting with symptoms of depression. Psychosomatics 1995; 36: 471-9.
3. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995; 10: 564-8.
4. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000; 47: 137-43.
5. Finlay I. Ketamine and its role in cancer pain. Pain Reviews 1999; 6: 303-13.
6. Fallon MT, Welsh J. The role of ketamine in pain control. European Journal of Palliative Care 1996; 3: 143-6.
7. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000; 95: 575-90.
8. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The effects of a subanaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000; 22: 293-302.
9. Alder CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646-9.
10. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: Promise and pitfalls. Pharmacopsychiatry 1998; 31 (suppl 2): 104-9.
11. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
12. Jansen KLR. A review of the nonmedical use of ketamine: Use, users and consequences. Journal of Psychoactive Drugs 2000; 32: 419-33.
13. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C et al. A double-blind that of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalised AIDS patients. AM J Psychiatry 1996; 153: 231-7.
14. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. Arch Intern Med 2000; 160: 786-94.